2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
The Motley Fool
AUGUST 23, 2023
Takeda's low valuation reflects a handful of important risks, such as key patent headwinds for top-selling drugs like Vyvanse, along with the company's highly leveraged balance sheet. Large-cap pharma stocks, after all, trade at an average earnings multiple of 15.1.
Let's personalize your content